Consider Epinephrine 0.3mg IM if there is any concern this could be allergic in nature
Consider Glucagon 1-5mg IV if patient is on beta-blockers and not responding to Epinephrine
Consider Tranexamic acid (1 g IV, over 10 min) for bradykinin-mediated<unk>  
FFP for possible etiology related to bradykinin or C1-esterase deficiency
2 units
Consider definitive airway if voice change, hoarseness, stridor, dyspnea
Prepare for a difficult airway which can include need for fiberoptics, ENT/anesthesia assistance, surgical airway, or transfer to the OR
2 units
Prepare for a difficult airway which can include need for fiberoptics, ENT/anesthesia assistance, surgical airway, or transfer to the OR
C1 inhibitor (C1INH)
1000 units if ≤50kg
1500 units if >50-75kg
2000 units if >75-100kg
2500 units if >100kg
Ecallantide
10mg SQ x 3 in different anatomical locations (30mg in total)
Icatibant
30mg SQ
1000 units if ≤50kg
1500 units if >50-75kg
2000 units if >75-100kg
2500 units if >100kg
10mg SQ x 3 in different anatomical locations (30mg in total)
30mg SQ
Typical anaphylaxis medications do not affect bradykinin levels, but consider:
Epinephrine 0.3mg IM
Diphenhydramine 50mg IV
Methylprednisolone 125mg IV
Consider Tranexamic acid (1 g IV, over 10 min) for bradykinin-mediated<unk>  
Icatibant
30mg SQ
Significantly decreases time to complete resolution (8 hrs vs 27.1 hrs)
Note: control group did not receive FFP
Consider Ecallantide
10mg SQ x 3 in different anatomical locations (30mg in total)
A 2015 trial showed a non-statistically significant trend towards increased rate of ED discharge
No benefit seen in mild-moderate cases in multi-center, double blind study
Epinephrine 0.3mg IM
Diphenhydramine 50mg IV
Methylprednisolone 125mg IV
30mg SQ
Significantly decreases time to complete resolution (8 hrs vs 27.1 hrs)
Note: control group did not receive FFP
10mg SQ x 3 in different anatomical locations (30mg in total)
A 2015 trial showed a non-statistically significant trend towards increased rate of ED discharge
No benefit seen in mild-moderate cases in multi-center, double blind study
Angioedema
Allergic reaction/urticaria
Lymphedema
Anaphylaxis
Lymphangitis
Cyanosis
Anxiety attack
Asthma exacerbation